TME Pharma N.V.

Novartis To Target COVID-19 Cytokine Storm With Jakavi Novartis AG is to launch a Phase III trial of Jakavi (ruxolitinib) to treat cytokine storm, the severe immune overreaction seen in some COVID-1

Serial entrepreneur Don deBethizy tells Mike Ward during BIO-Europe 2018 that European biotech can prosper if management teams take a global view. Having crossed the Atlantic six years ago to settle i

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

The renal anemia market has stalled in recent years after safety concerns with, and biosimilar competition to, the old mainstay erythropoiesis-stimulating agents (ESA) put pressure on overall sales, b